Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims is from April 29, 2025, to June 23, 2025 [2]. - The complaint claims that Hims engaged in deceptive promotion and selling of knockoff versions of Wegovy, risking patient safety [2]. - There is a substantial risk that the collaboration with Novo Nordisk could be terminated due to these practices [2]. - The positive statements made by the defendants regarding the company's business and operations were materially misleading and lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased HIMS shares during the class period are encouraged to register for potential lead plaintiff appointment [1][3]. - The deadline for shareholders to register is August 25, 2025, and there is no cost or obligation to participate [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for allegedly making false statements and engaging in deceptive practices related to the promotion and sale of Wegovy®, leading to a significant drop in stock price after the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, to seek lead plaintiff status [1][4]. - The lawsuit alleges that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [2][3]. - Following the announcement of the partnership termination by Novo Nordisk on June 23, 2025, Hims & Hers' stock price fell by more than 34% [3]. Group 2: Company Background - Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by August 25, 2025, to serve as lead plaintiff [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo and the offerings of compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - The complaint specifies that Hims failed to disclose that its communication with Novo Nordisk was not as beneficial as portrayed, potentially jeopardizing the long-term collaboration for access to Wegovy [4]. - It is alleged that Hims misrepresented the approval of its compounded semaglutide products by Novo Nordisk, which could mislead investors about the company's product offerings [4]. - The lawsuit highlights that Hims made positive statements about its partnership with Novo, which were not supported by the actual circumstances surrounding the collaboration [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, due to these deceptive practices, leading to a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the class period (April 29, 2025, to June 23, 2025) can seek to be appointed as lead plaintiff in the lawsuit [4] - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 [5]

Group 1 - The core viewpoint is that Hims & Hers is transitioning from being perceived merely as a telemedicine company to a comprehensive, data-driven precision health platform with software-like economics and predictable recurring revenue [1] - The company is experiencing increasing operating leverage, which indicates a potential for higher profitability as it scales [1] - The narrative surrounding Hims & Hers is often misunderstood, with the market not fully pricing in its long-term potential and scalable business model [1] Group 2 - The investment approach emphasizes a fundamental, bottom-up strategy focusing on market psychology, business durability, and valuation discipline [1] - The company is particularly appealing due to its scalable models and durable competitive advantages, which are often overlooked by investors [1] - The investment philosophy highlights the nonlinear nature of investing success, shaped by cycles and constant recalibration [1]

Core Viewpoint - Hims & Hers Health (NYSE: HIMS) faces significant challenges following a drop in share price due to an FTC investigation into its advertising practices and the termination of a collaboration with Novo Nordisk, which raised safety concerns regarding its weight-loss drug offerings [1][2][5]. Group 1: Company Challenges - The share price of Hims & Hers dropped significantly in after-hours trading after reports of an FTC probe into its advertising practices and subscription cancellation difficulties [1]. - Novo Nordisk ended its collaboration with Hims, citing serious accusations that Hims was jeopardizing patient safety, which has led to a pending securities class action lawsuit against the company [2][4]. - Following the termination of the partnership, Hims' stock price fell more than 34% on June 23, 2025 [5]. Group 2: Financial Performance - Hims reported total revenue of $545 million for Q2 2025, reflecting a 7% sequential decline [6]. - Revenue from compounded GLP-1 weight-loss drugs decreased to $190 million from $230 million in the previous quarter [6]. - The revenue per subscriber fell to $74 from $84, attributed to the off-boarding of some GLP-1 subscribers [6]. Group 3: Legal and Regulatory Issues - A class action complaint alleges that Hims made false and misleading statements regarding its promotion of illegitimate versions of Wegovy, which posed safety risks to patients [4]. - Hagens Berman is investigating claims from investors who suffered substantial losses during the class period from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [3][7].

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that negatively impacted investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Hims & Hers Health, Inc. engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - It is alleged that this misconduct posed a significant risk of terminating the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis due to the aforementioned issues [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be eligible for compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Hims & Hers Health Inc. is facing potential securities fraud claims following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3] Group 1: Legal Investigation - Berger Montague is investigating Hims & Hers for potential securities fraud claims, particularly regarding misleading statements made during the Class Period from April 29, 2025, to June 22, 2025 [1][3] - Investors who acquired Hims & Hers securities during the Class Period have until August 25, 2025, to seek appointment as lead plaintiff representatives [1] Group 2: Partnership Termination - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive marketing practices and the sale of unapproved compounded versions of semaglutide [2] - Following the announcement, Hims & Hers shares dropped over 34% in intraday trading, indicating significant investor concern regarding regulatory compliance and reputational risks [2] Group 3: Allegations of Misleading Statements - The lawsuit alleges that Hims & Hers made materially false or misleading statements about the nature and regulatory status of its GLP-1 offerings and the risks associated with its partnership with Novo Nordisk [3] - The investigation is focused on whether Hims & Hers and certain executives violated federal securities laws by providing false or misleading information to investors [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, affecting investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo and the implications for Hims subscribers' access to the weight-loss drug Wegovy [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]